Max Healthcare Q2 net profit falls 15.6% on higher operating, tax expenses
Max Healthcare moved higher in a quarterly results development for Q2FY27.
· BS Companies
Max Healthcare's Q2FY27 net profit declined 15.6 per cent to ₹414.45 crore as operating and tax expenses rose, even as revenue grew 16.8 per cent on higher patient demand.
Key facts
- Period
- Q2FY27
The analysis
Max Healthcare reported ₹414.45 crore for Q2FY27, with movement of 15.6% and 16.8% attached to those lines. Those are the figures as filed — what moves the price is how they sit against what the market already expected, not their absolute size.
Against that, the stock is +1.0% on the day at ₹860.00, and has returned -23.5% over three months. It sits 27% below its 52-week high, which means a good deal of bad news was already in the price. The pharma & healthcare sector has moved -0.9% over the same period, so Max Healthcare is running 22.6 points behind its peers.
For Max Healthcare, the question is how much of this is already reflected in the price and how much re-rates the pharma & healthcare peer set alongside it.
Why it matters
- Earnings versus expectations is what actually re-rates a stock; the surprise matters more than the absolute number.
Market context
- In focus: Max Healthcare (MAXHEALTH), in Pharma & Healthcare.
- Over three months: Max Healthcare -23.5% against Pharma & Healthcare -0.9% (22.6 points behind).
- At least 25% below the 52-week high: Max Healthcare (27%).
- Trading well above normal today: Max Healthcare at 2.0 times its 20-day average volume.
| Company | Price | Day | 1M | 3M | From 52-wk high | Volume vs 20-day | Market cap |
|---|---|---|---|---|---|---|---|
| Max HealthcareMAXHEALTH · Pharma & Healthcare | ₹860.00 | +1.0% | -7.5% | -23.5% | -27.2% | 2.0× | — |
Pharma & Healthcare
1M -0.6% · 3M -0.9%
Max Healthcare
Prices as of 30 Oct 2026, 16:10 IST. Sector moves are the average of the stocks we track in each sector.
In this story
Related coverage
Max Healthcare Q2 PAT rises 10% to ₹448 cr on higher bed occupancy
Q2 Results Live: Varun Beverages Q3 Net Profit Rises 14% YoY; Reliance Slips, Sun Pharma Gains Ahead Of Earnings
Laurus Labs shares climb 4% after Q2 profit zooms 126% YoY
Laurus Labs Q2 Review: Brokerages Split As Jefferies Raises Target, Two Retain Sell
India's pharma, healthcare deal volumes rise 23% in Q3 2026: Report